Viridium Acquires Its ACMPR Licensed Facility Lands
Calgary, Alberta (FSCwire) - Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR, OTCPink: MRRBD) announces that Viridium, through a special wholly-owned subsidiary, has acquired the property, near Mission, BC, upon which its current Access to Cannabis for Medical Purposes Regulations (“ACMPR”) licensed facility is located.
The property acquired near Mission, BC (the “Mission Property”), was previously leased by Experion Biotechnologies Inc. (“Experion”), a wholly-owned subsidiary of Viridium, and for which Experion held an option to purchase the Mission Property for a purchase price of $1,000,000 (the “Option”). The Option was exercised and the land acquisition of the Mission Property was completed on November 3, 2017. The total acquisition price after transfer taxes and other adjustments was $1,016,380.82. The acquired lands were registered in the name of Viridium’s wholly owned subsidiary, Fish Trap Ventures Ltd. (“Fish Trap”). Fish Trap is now the Fee Simple owner of the Mission Property.
The Mission Property is approximately ten (10) acres. The Mission Property hosts the Company’s purpose build ACMPR licensed facility to produce cannabis. Viridium management believes that, as a growing location, the Mission Property has natural advantages, such as approximately 1,900 hours of annual sunshine, zoned in ALR, access to high-quality natural water sources, moderate temperatures, and available land for expansion, highly affordable hydro-electricity, close proximity to the TransCanada Highway, and access to multiple points of distribution. Initial work has commenced at the Mission Property in preparation for the erection of an approximate 40,000 square-foot greenhouse canopy to expand the medical-grade cannabis production at the Mission Property, subject to Health Canada approval.
Jarrett Malnarick (COO of Viridium) stated “acquiring the lands ensures us of control over our future developments on the Mission Property, providing us with the certainty that our future development at the Mission Property can proceed fully under the control of Viridium with site preparations now proceeding as planned.”
About Viridium
Viridium wholly owns Experion Biotechnologies Inc. which has been granted by its license to produce medical cannabis by Health Canada. Experion is actively proceeding to meet the Health Canada requirements to amend its current license to include the license to sell medical cannabis.
More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.
Disclosure
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
For further information:
VIRIDIUM PACIFIC GROUP LTD.
Damian Wojcichowsky
Telephone: 647 464 3596
Email: Damian@viridiumpacific.com
To view this press release as a PDF file, click onto the following link:public://news_release_pdf/Viridium11062017_0.pdf
Source: Viridium Pacific Group Ltd. (TSX Venture:VIR)
To follow Viridium Pacific Group Ltd. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2017 Filing Services Canada Inc.